Pharmaceuticals (Feb 2023)

Nornidulin, A New Inhibitor of <i>Plasmodium falciparum</i> Malate: Quinone Oxidoreductase (<i>Pf</i>MQO) from Indonesian <i>Aspergillus</i> sp. BioMCC f.T.8501

  • Alfian Wika Cahyono,
  • Loeki Enggar Fitri,
  • Sri Winarsih,
  • Erwahyuni Endang Prabandari,
  • Danang Waluyo,
  • Amila Pramisandi,
  • Evita Chrisnayanti,
  • Diana Dewi,
  • Eka Siska,
  • Nurlaila Nurlaila,
  • Nuki Bambang Nugroho,
  • Tomoyoshi Nozaki,
  • Suciati Suciati

DOI
https://doi.org/10.3390/ph16020268
Journal volume & issue
Vol. 16, no. 2
p. 268

Abstract

Read online

This study aimed to obtain a microbial active compound as a novel antimalarial drug from Indonesian isolates. Target-based assays were used to screen for antimalarial activity against the parasite mitochondrial, Plasmodium falciparum malate:quinone oxidoreductase (PfMQO) enzyme. In total, 1600 crude extracts, composed from 800 fungi and 800 actinomycetes extracts, were screened against PfMQO, yielding six active extracts as primary hits. After several stages of stability tests, one extract produced by Aspergillus sp. BioMCC f.T.8501 demonstrated stable PfMQO inhibitory activity. Several purification stages, including OCC, TLC, and HPLC, were performed to obtain bioactive compounds from this active extract. All purification steps were followed by an assay against PfMQO. We identified the active compound as nornidulin based on its LC-MS and UV spectrum data. Nornidulin inhibited PfMQO activity at IC50 of 51 µM and P. falciparum 3D7 proliferation in vitro at IC50 of 44.6 µM, however, it had no effect on the growth of several mammalian cells. In conclusion, we isolated nornidulin from Indonesian Aspergillus sp. BioMCC f.T.8501 as a novel inhibitor of PfMQO, which showed inhibitory activity against the proliferation of P. falciparum 3D7 in vitro.

Keywords